News, Insights & What’s
Next in Specialty Care
Explore expert perspectives, thought leadership, and news on the trends shaping specialty healthcare. From emerging therapies and new drug developments to evolving care models, market shifts, and the issues and opportunities affecting manufacturers and providers.
Anti-amyloid therapies are reshaping neurology infusion by requiring coordinated systems for patient selection, imaging, medication access, monitoring, purchasing, and caregiver communication well beyond the infusion itself.
Immune globulin continues to expand across home and alternate-site care as long-term treatment needs, greater patient flexibility, mature specialty pharmacy infrastructure, and evolving reimbursement create more ways to deliver IVIG and SCIG beyond traditional hospital settings.
The immunoglobulin market is becoming more segmented as IVIG, conventional SCIG, and facilitated SCIG expand across different care settings, distribution channels, reimbursement models, and patient preferences.
As immunoglobulin therapy expands across physician offices, infusion centers, specialty pharmacies, and patients’ homes, providers must balance clinical suitability with payer requirements, purchasing pathways, and individual patient preferences.
Class of trade helps pharmaceutical manufacturers structure specialty contracting strategies around the distinct purchasing models, distribution channels, and operational needs of different provider segments.
Site-of-care policies are moving specialty infusion across hospitals, physician practices, independent centers, and patients’ homes—reshaping pharmaceutical purchasing, contracting, distribution, reimbursement, and the treatment experience.
Pharmaceutical class of trade helps specialty providers, manufacturers, distributors, and GPOs identify how an organization operates so the right locations can connect with the manufacturer programs, contract pricing, and purchasing pathways designed for them.
Payer policies increasingly shape how IBD infusion therapy is approved, acquired, and delivered, creating operational challenges for GI practices while influencing treatment access, site of care, and continuity for patients.
Buy-and-bill gives GI practices greater control over infusion care while exposing them to inventory costs, reimbursement delays, and payer changes. Sustainable programs depend on aligning pharmaceutical purchasing, actual collections, and the full cost of delivering treatment.
Stay Informed.
Stay Better Aligned.
Explore how AlignedCareGPO helps create stronger alignment between manufacturers, members, specialty distribution, and program execution to drive greater value across specialty healthcare.








